Darifenacin: in the treatment of overactive bladder.

Abstract

Darifenacin is a selective muscarinic M3-receptor antagonist that has been evaluated in clinical trials in patients with overactive bladder syndrome (OAB) using a controlled-release formulation. In multicentre, randomised, double-blind trials in patients with OAB, darifenacin 7.5 or 15 mg once daily for 12 weeks significantly reduced the frequency of urinary incontinence, frequency of micturition and frequency and severity of urgency versus placebo. A significant difference from placebo was apparent 2 weeks after starting treatment. At a dosage of 30 mg once daily, darifenacin significantly prolonged warning time compared with placebo. Darifenacin 15 mg once daily for 2 weeks was as effective as oxybutynin 5 mg three times daily at reducing the frequency of urinary incontinence and frequency and severity of urgency in patients with OAB. Darifenacin was generally well tolerated in clinical trials. The most common adverse events were dry mouth and constipation. CNS tolerability appeared to be similar to that of placebo. Darifenacin had no adverse effect on cognitive function in healthy elderly volunteers.

• Authors: Katherine F Croom, Gillian M Keating
• Journal: Drugs & aging (Drugs Aging) Vol. 21 Issue 13 Pg. 885-92; discussion 893-4 ( 2004) ISSN: 1170-229X [Print] New Zealand
• PMID: 15493952 (Publication Type: Journal Article, Review)

Chemical References

• Benzofurans
• Pyrrolidines
• Receptor, Muscarinic M3
• darifenacin

Topics

• Adult
• Aged
• Area Under Curve
• Benzofurans (metabolism, pharmacokinetics, therapeutic use)
• Biological Availability
• Female
• Half-Life
• Humans
• Male
• Middle Aged
• Pyrrolidines (metabolism, pharmacokinetics, therapeutic use)
• Randomized Controlled Trials as Topic
• Receptor, Muscarinic M3 (antagonists & inhibitors)
• Severity of Illness Index
• Tissue Distribution
• Treatment Outcome
• Urinary Incontinence (classification, drug therapy, physiopathology)